

**Wright Medical Group, Inc.**  
**Reconciliation of Net Sales to Net Sales Excluding the Impact of Foreign Currency**  
(dollars in thousands--unaudited)

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>June 30, 2009</b>		<b>June 30, 2009</b>	
	<b>International Net Sales</b>	<b>Total Net Sales</b>	<b>International Net Sales</b>	<b>Total Net Sales</b>
<b>Net sales, as reported</b>	\$ 45,779	\$ 118,926	\$ 92,338	\$ 239,838
Currency impact as compared to prior period	3,082	3,082	6,419	6,419
<b>Net sales, excluding the impact of foreign currency</b>	<u>\$ 48,861</u>	<u>\$ 122,008</u>	<u>\$ 98,757</u>	<u>\$ 246,257</u>

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(in thousands, except per share data--unaudited)

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>June 30, 2009</b>	<b>June 30, 2008</b>	<b>June 30, 2009</b>	<b>June 30, 2008</b>
<b>Operating Income</b>				
<b>Operating income (loss), as reported</b>	\$ 5,241	\$ (448)	\$ 11,234	\$ 5,535
<i>Reconciling items impacting Gross Profit:</i>				
Inventory step-up amortization	30	-	60	73
Non-cash, stock-based compensation	311	308	603	652
Total	<u>341</u>	<u>308</u>	<u>663</u>	<u>725</u>
<i>Reconciling items impacting Selling, General and Administrative expenses:</i>				
Non-cash, stock-based compensation	3,204	2,846	5,305	5,817
U.S. governmental inquiries	2,007	1,462	6,074	3,186
Appellate court decision	-	2,346	-	2,346
Total	<u>5,211</u>	<u>6,654</u>	<u>11,379</u>	<u>11,349</u>
<i>Reconciling items impacting Research and Development expenses:</i>				
Non-cash, stock-based compensation	565	417	960	666
<i>Other Reconciling Items:</i>				
Restructuring charges	794	3,095	860	4,910
Acquired in-process research and development	-	2,490	-	2,490
Total	<u>794</u>	<u>5,585</u>	<u>860</u>	<u>7,400</u>
<b>Operating income, as adjusted</b>	<u>\$ 12,152</u>	<u>\$ 12,516</u>	<u>\$ 25,096</u>	<u>\$ 25,675</u>
<b>Operating income, as adjusted, as a percentage of net sales</b>	<u>10.2%</u>	<u>10.6%</u>	<u>10.5%</u>	<u>11.0%</u>

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
**(continued)**

	<u>Three Months Ended</u>		<u>Six Months Ended</u>	
	<u>June 30, 2009</u>	<u>June 30, 2008</u>	<u>June 30, 2009</u>	<u>June 30, 2008</u>
<b>Net Income</b>				
<b>Net income (loss), as reported</b>	\$ 2,427	\$ (2,357)	\$ 5,744	\$ 1,701
<i>Pre-tax impact of reconciling items:</i>				
Non-cash, stock-based compensation	4,080	3,571	6,868	7,135
Restructuring charges	794	3,095	860	4,910
Inventory step-up amortization	30	-	60	73
U.S. governmental inquiries	2,007	1,462	6,074	3,186
Appellate court decision (including interest)	-	2,638	-	2,638
Acquired in-process research and development	-	2,490	-	2,490
<b>Total</b>	<u>6,911</u>	<u>13,256</u>	<u>13,862</u>	<u>20,432</u>
<i>Tax effect of reconciling items:</i>				
Non-cash, stock-based compensation	(1,164)	(1,061)	(2,037)	(1,980)
Restructuring charges	(309)	(1,067)	(335)	(1,730)
Inventory step-up amortization	(12)	-	(23)	(29)
U.S. governmental inquiries	(784)	(576)	(2,373)	(1,256)
Appellate court decision	-	(1,039)	-	(1,039)
Acquired in-process research and development	-	-	-	-
<b>Total</b>	<u>(2,269)</u>	<u>(3,743)</u>	<u>(4,768)</u>	<u>(6,034)</u>
<b>Net income, as adjusted</b>	<u>\$ 7,069</u>	<u>\$ 7,156</u>	<u>\$ 14,838</u>	<u>\$ 16,099</u>

	<u>Three Months Ended</u>		<u>Three Months Ended</u>	
	<u>June 30, 2009</u>		<u>June 30, 2008</u>	
	<u>As Reported</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>As Adjusted</u>
<b>Basic net income (loss)</b>	\$ 2,427	\$ 7,069	\$ (2,357)	\$ 7,156
Interest expense on convertible notes	N/A	935	N/A	937
<b>Diluted net income (loss)</b>	\$ 2,427	\$ 8,004	\$ (2,357)	\$ 8,093
<b>Basic shares</b>	37,332	37,332	36,832	36,832
Dilutive effect of stock options and restricted shares	72	72	-	663
Dilutive effect of convertible notes	N/A	6,126	-	6,126
<b>Diluted shares</b>	37,404	43,530	36,832	43,621
<b>Net income (loss) per share, diluted</b>	<u>\$ 0.06</u>	<u>\$ 0.18</u>	<u>\$ (0.06)</u>	<u>\$ 0.19</u>

**Wright Medical Group, Inc.**  
**Reconciliation of As Reported Results to Non-GAAP Financial Measures**  
(continued)

	<b>Six Months Ended</b>		<b>Six Months Ended</b>	
	<b>June 30, 2009</b>		<b>June 30, 2008</b>	
	<u>As Reported</u>	<u>As Adjusted</u>	<u>As Reported</u>	<u>As Adjusted</u>
<b>Basic net income</b>	\$ 5,744	\$ 14,838	\$ 1,701	\$ 16,099
Interest expense on convertible notes	N/A	1,870	N/A	1,874
<b>Diluted net income</b>	\$ 5,744	\$ 16,708	\$ 1,701	\$ 17,973
<b>Basic shares</b>	37,281	37,281	36,718	36,718
Dilutive effect of stock options and restricted shares	81	81	595	595
Dilutive effect of convertible notes	-	6,126	-	6,126
<b>Diluted shares</b>	37,362	43,488	37,313	43,439
<b>Net income per share, diluted</b>	<u>\$ 0.15</u>	<u>\$ 0.38</u>	<u>\$ 0.05</u>	<u>\$ 0.41</u>

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>June 30, 2009</b>	<b>June 30, 2008</b>	<b>June 30, 2009</b>	<b>June 30, 2008</b>
	<b>Net Income per Diluted Share</b>			
<b>Net income (loss), as reported, per diluted share</b>	\$ 0.06	\$ (0.06)	\$ 0.15	\$ 0.05
Interest expense on convertible notes	0.02	0.02	0.04	0.04
Dilutive effect of convertible notes	(0.01)	0.01	(0.02)	(0.01)
Non-cash, stock-based compensation	0.07	0.06	0.11	0.12
Restructuring charges	0.01	0.05	0.01	0.07
Inventory step-up amortization	0.00	-	0.00	0.00
U.S. governmental inquiries	0.03	0.02	0.09	0.04
Appellate court decision	-	0.04	-	0.04
Acquired in-process research and development	-	0.06	-	0.06
<b>Net income, as adjusted, per diluted share</b>	<u>\$ 0.18</u>	<u>\$ 0.19</u>	<u>\$ 0.38</u>	<u>\$ 0.41</u>

**Wright Medical Group, Inc.**  
**Reconciliation of Effective Tax Rate, As Reported, to Effective Tax Rate, As Adjusted**  
(unaudited)

	<b>Three Months Ended</b>		<b>Six Months Ended</b>	
	<b>June 30, 2009</b>	<b>June 30, 2008</b>	<b>June 30, 2009</b>	<b>June 30, 2008</b>
<b>Effective tax rate, as reported</b>	40.2%	(45.1%)	37.3%	70.4%
Non-cash, stock-based expense	(4.1%)	(3.9%)	(2.5%)	(4.0%)
Restructuring charges	(0.2%)	167.5%	0.2%	(16.2%)
Inventory step-up amortization	0.0%	-	0.0%	0.0%
U.S. governmental inquiries	(0.3%)	(0.7%)	0.6%	(0.6%)
Appellate court decision	-	(2.4%)	-	(0.8%)
Acquired in-process research and development	-	(76.9%)	-	(10.3%)
<b>Effective tax rate, as adjusted</b>	<u>35.6%</u>	<u>38.5%</u>	<u>35.6%</u>	<u>38.5%</u>